VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

(2011) Jenny J. Kim et al.   CANCER

Identification of cis - and trans -Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels

(2011) Stephanie Debette et al.   CIRCULATION RESEARCH

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

(2011) Jesus Garcia-Donas et al.   LANCET ONCOLOGY

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

(2010) K.D. Steffensen et al.   GYNECOLOGIC ONCOLOGY

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

(2010) T F Hansen et al.   PHARMACOGENOMICS JOURNAL

VEGF −460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma

(2010) M-H Chen et al.   PHARMACOGENOMICS JOURNAL

Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer

(2010) Torben Frøstrup Hansen et al.   VIRCHOWS ARCHIV

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

(2010) Susan A. J. Vaziri et al.   Current Oncology Reports

Structure and function of VEGF receptors

(2009) Edward Stuttfeld et al.   IUBMB LIFE

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of theVEGF-A936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer

(2009) Jean-Louis Formento et al.   PHARMACOGENOMICS

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

(2009) F. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

(2008) A. M. Schultheis et al.   CLINICAL CANCER RESEARCH

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet’s disease

(2008) M. Kamoun et al.   TISSUE ANTIGENS